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Abstract
Background: Distant metastasis resulting from vascular dissemination of cancer cells is the primary cause of mortality
from breast cancer. We have previously reported that E-selectin expression on the endothelial cell surface mediates
shear-resistant adhesion and migration of circulating cancer cells via interaction with CD44. As a result of shedding,
soluble E-selectin (sE-selectin) from the activated endothelium is present in the serum. In this study, we aimed to
understand the role of sE-selectin in tumor progression and metastasis.
Methods: We investigated the effect of sE-selectin on shear-resistant adhesion and migration of metastatic breast
cancer cells and leukocytes in vitro and in vivo.
Results: We found that sE-selectin promoted migration and shear-resistant adhesion of CD44+/high breast cancer cell
lines (MDA-MB-231 and MDA-MB-468) to non-activated human microvessel endothelial cells (ES-HMVECs), but not of
CD44-/low breast cancer cell lines (MCF-7 and T-47D). This endothelial E-selectin independent, sE-selectin-mediated
shear-resistant adhesion was also observed in a leukocyte cell line (HL-60) as well as human peripheral blood
mononuclear cells (PBMCs). Additionally, the incubation of MDA-MB-231 cells with sE-selectin triggered FAK
phosphorylation and shear-resistant adhesion of sE-selectin-treated cells resulted in increased endothelial
permeabilization. However, CD44 knockdown in MDA-MB-231 and HL-60 cells resulted in a significant reduction of
sE-selectin-mediated shear-resistant adhesion to non-activated HMVECs, suggesting the involvement of CD44/FAK.
Moreover, functional blockade of ICAM-1 in non-activated HMVECs resulted in a marked reduction of sE-selectin-mediated
shear-resistant adhesion. Finally, the pre-incubation of CD44+ 4 T1 murine breast cancer cells with sE-selectin augmented
infiltration into the lung in E-selectin K/O mice and infusion of human PBMCs pre-incubated with sE-selectin stimulated
MDA-MB-231 xenografted breast tumor growth in NSG mice.
Conclusions: Our data suggest that circulating sE-selectin stimulates a broad range of circulating cells via CD44 and
mediates pleiotropic effects that promote migration and shear-resistant adhesion in an endothelial E-selectin
independent fashion, in turn accelerating tissue infiltration of leukocytes and cancer cells.
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Background
Tissue infiltration of circulating cells is critical for
multiple aspects of tumor progression and metastasis.
First, extravasation of circulating leukocytes into the
primary tumor aids in the development of a tumor
stroma that provides a fertile environment for cancer
cells to survive and grow. Second, extravasation of circu-
lating tumor cells into the tissue parenchyma of distant
organs gives rise to metastasis. Despite the recognized
importance of tissue infiltration in tumor progression
and metastasis as well as pathologic alterations in the
global serum protein profiles of cancer patients, it is un-
certain whether circulating factors in the vascular space
extrinsically stimulate circulating cells to infiltrate tissues.
During tissue infiltration, inflamed vascular endothelium,
characterized by expression of E-selectin and CAMs,
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functions as a gateway to tissue parenchyma. Tissue
infiltration by circulating cells is governed by a multi-step
adhesion cascade, mediated by sequential interactions and
crosstalk between adhesion molecules expressed on the
endothelial cell surface and their counter-receptor ligands
expressed on circulating cells [1–4]. A robust interaction
is required for this attachment to resist swift blood flow.
Weak interaction prevents effective attachment of the
circulating cells to the endothelial surface. The initial
adhesion of circulating cells subsequently leads to firm
attachment that opens the endothelial junction enabling
transendothelial migration into tissue parenchyma toward
cytokine or chemokine stimuli [5, 6].
Adhesion molecules, such as selectins, ICAM, and
VCAM, expressed on the endothelial surface in response
to inflammatory stimuli are the primary mediators of
tissue infiltration [7, 8]. E-selectin (CD62E, ELAM-1, or
LECAM-2) is expressed exclusively on the luminal
surfaces of inflamed vasculature [9] and mediates rolling
and vascular adhesion through interaction with carbohy-
drate ligands [10, 11]. A variety of ligands for E-selectin
have been identified in different types of cells; these
include CD44 (HCELL) [12–14], Mac-2 binding protein
[15], Muc-1 [16], death receptor-3 [17], and ESL-1 [18].
The expression of E-selectin is temporally and spatially
limited. E-selectin is shed into circulation (soluble E-
selectin: sE-selectin) or internalized rapidly after activation.
An abundance of sE-selectin in the serum is indicative of
inflammation [19–23], and circulating sE-selectin levels are
consistently high among individuals with chronic inflam-
mation compared to their healthy counterparts [24]. Simi-
larly, elevated serum levels of sE-selectin were reported
and positively associated with tumor grade, tumor stage,
and metastases in breast cancer [3, 25]. Despite the positive
associations between sE-selectin and breast cancer pro-
gression and metastasis, it is unclear whether sE-selectin
plays any functional role in tumor progression. In the
present study, we demonstrate that sE-selectin functions as
a signaling molecule in circulation with the ability to 1) en-
hance shear-resistant adhesion and migration of CD44+/high
breast cancer cells (BCs) and leukocytes in an endothelial
E-selectin independent fashion, 2) activate focal adhesion
kinase (FAK), 3) promote homing of CD44+/high BCs to the
lung, and 4) stimulate tumor growth and intratumoral in-
filtration of PBMCs. These findings identify a possible ex-
trinsic mechanism by which an inflammation-associated
factor (i.e., sE-selectin) present in circulation pleiotropically
stimulates circulating tumor cells toward tumor progres-
sion and metastasis.
Methods
Cell lines and culture conditions
Human breast cancer cell lines MDA-MB-231, MDA-
MB-468, T-47D, and MCF-7, human leukocyte cell line
HL-60, and murine breast cancer cell line 4 T1 were
purchased from ATCC (Rockville, MD). MDA-MB-231,
MDA-MB-468, MCF-7, and 4 T1 cells were cultured in
Dulbecco’s Modified Eagle Medium (DMEM; Cellgro)
supplemented with 10 % fetal bovine serum (FBS),
2 mM GlutaMAX, and 100U/ml Penicillin-Streptomycin
(Life Technology, Grand Island, NY). T-47D and human
PBMCs cells were cultured in RPMI-1640 supplemented
with 10 % FBS, 2 mM GlutaMAX, and 100U/ml Penicillin-
Streptomycin. HL-60 cells were cultured in IMDM supple-
mented with 20 % FBS, 100U/ml Penicillin-Streptomycin,
and Insulin-Transferrin-Selenium (100 mg/L Insulin;
5.5 mg/L Transferrin; 6.7 μg/L Selenium; Corning,
Manassas, VA). CD44 knockdown clones were gener-
ated by transducing the cells with CD44 shRNA lenti-
virus or control shRNA (Santa Cruz, CA), followed
by selection with puromycin. 4 T1-Luc was generated
by transducing 4 T1 cells with luciferase lentivirus
(Capital Biosciences) followed by selection using 6 μg/
ml puromycin (InvivoGen). Human Microvascular Endo-
thelial cells (HMVECs) and E-selectin-expressing Tet-on
inducible HMVECs [26] were cultured in endothelial basal
medium-2 (EBM-2; Lonza) supplemented with 2 % tet-
approved FBS and an EGM SingleQuot Kit containing epi-
dermal growth factor (EGF), hydrocortisone, gentamicin,
and amphotericin B (GA-1000; Lonza). All cells were
cultured in 5 % CO2 humid chambers at 37 °C.
Reagents and antibodies
Recombinant human sE-selectin was purchased from
R&D Systems. Monoclonal antibodies for pFAK and
total FAK were purchased from Cell Signaling. Blocking
antibodies for ICAM and VCAM were purchased from
Santa Cruz and Biolegend, respectively. FAK inhibitor II
was purchased from Calbiochem.
In vitro cell adhesion assay
HMVECs were grown to confluence in the flow chamber
(μ-Slide I 0.4 Luer for cancer cells and 0.2 for leukocytes;
Ibidi, Madison, WI) coated with collagen I and fibronec-
tin. The cells (105 cells/ml) were pre-incubated with 100
nM sE-selectin for 10 min and perfused over a 5 min
period into the flow chamber in 1 % FBS containing
DMEM medium at a shear stress rate of 1 dyn/cm2.
Unbound cells were washed off with DMEM containing
1 % FBS. Using a light microscope at a final magnifica-
tion of 100×, the number of cells that adhered to endo-
thelial cells was determined by counting cells in at least
five random fields. The data are expressed as the mean
of triplicate experiments.
In vitro permeability assay
HMVECs were grown to confluence on the top-facing
side of a collagen-coated 0.4-μm-pore transwell chamber
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(Corning). MDA-MB-231 cells were pre-incubated with
100 nM sE-selectin for 10 min at 37 °C. MDA-MB-231
cells (2 × 103 cells) suspended in EBM-2 media and
2000-kDa FITC-dextran (final concentration of 1 mg/ml,
Sigma-Aldrich) were seeded into the upper chamber,
and 600 μl EBM-2 media was added to lower chamber.
Then, at the indicated time points, 50-μl aliquots were
removed from the lower chamber and the fluorescence
was measured at 485/530 nm with a CLARIOstar
fluorimeter (BMG Labtech).
Cell migration assay
Transwell migration assays were performed using a
12.0-μm or 5.0-μm pore transwell chamber (Becton
Dickinson). Cancer cells (2.5 × 104 cells) or leukocytes
(1.0 × 105 cells) suspended in serum-free media were
applied to the upper chamber and 100 nM sE-selectin
was added to the lower chamber. After overnight incu-
bation at 37 °C, migrated cells were stained using a
HEMA 3 staining kit (Pierce) and counted under a light
microscope.
Anoikis assay
Anoikis resistance was measured using ultra-low attach-
ment plates (Corning). Cancer cells (104 cells) were sus-
pended in 1 % FBS containing medium with or without
sE-selectin, seeded into 96-well ultra-low attachment
plates, and incubated for 72 h. The number of viable and
non-viable cells was determined by trypan blue exclusion
using a hemocytometer.
Animal models
All animal housing and handling procedures were in ac-
cordance with institutional guidelines at the University
of Oklahoma and Thomas Jefferson University. Six-
week-old female Balb/C mice (Jackson Laboratory) or E-
selectin knockout mice (C.129S4-Seletm1Dmil/J; Jackson
Laboratory) were used for the in vivo cell adhesion
assay. Female Balb/C mice or E-selectin knockout mice
(n = 3) were injected intravenously with 4 T1-luc murine
breast cancer cells (3 × 104 in 100 μl saline) via tail vein.
Cancer cells were pre-incubated with 100 nM sE-
selectin for 10 min at 37 °C and washed with PBS to
remove sE-selectin carry over before injection. Seven
days later, whole lungs were harvested and total RNA
was isolated using TRIzol (Life Technologies). Total
RNA was reverse transcribed using random hexamer
primers and SuperScript® III First-Strand Synthesis
Supermix (Life Technologies). qPCR reactions (80 cycle)
were performed using TaqMan gene expression master
mix (Life Technologies) and the Biorad CFX96™ Touch
Real-Time PCR Detection System (Biorad). Luciferase and
mouse GAPDH primers were used (Life Technologies).
Data are presented as delta-Ct relative to an endogenous
control, GAPDH. For leukocyte infiltration, MDA-MB-
231 breast cancer cells were injected into the mammary
fat pads of 7-week-old female NOD SCID IL2 receptor
gamma chain knockout mice (NSG mice: NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ; Jackson Laboratory, Bar Harbor,
ME). Freshly isolated PBMCs from healthy donors were
incubated with 10 μM Calcein AM (BD bioscience, San
Jose, CA) for 30 min. After brief a wash, the Calcein posi-
tive PBMCs (2 × 107) were incubated with sE-selectin or
saline and slowly infused over 1 min via tail vein into NSG
mice bearing tumors of approximately 300 mm3(LxWxH).
Tumors were harvested to analyze the tissue migration of
Calcein-labeled PBMCs. For tumor growth, MDA-MB-
231-TGL cell line (a kind gift from Dr. Massague, Memor-
ial Sloan-Kettering Cancer Center) was used. Human
PBMCs (1 × 107 cells) that were treated with or without
sE-selectin were infused via tail vein once a week. Tumor
growth was monitored by measuring bioluminescence
using IVIS Lumina XR (Caliper, MA) once a week by
intraorbital injection of 100 μl luciferase (15 μg/ml).
Flow cytometry
Human CD44-APC (IM7) conjugated antibody (BD
Biosciences, CA) was used to select shRNA-infected
cells using a Coulter MoFlo cell sorter (Beckman
Coulter, Brea, CA). For phenotypic analysis of human
PBMCs, tissue was homogenized in cold RPMI, filtered
through a 50-μm cell strainer, and washed in PBS. The
single cell homogenates were incubated with conjugated
antibodies (CD4-APCeFluor780, CD45-FITC, CD8-
PerCPCy5.5, CD14-PE, and CD11c-APC) for 20 min at
4 °C. Cells were analyzed on an LSRII flow cytometer
(BD Bioscience). All data were analyzed with FlowJo
software.
Statistical analysis
All experiments were carried out in triplicate and
repeated at least twice independently. The results are
presented as Mean ± SD. Comparisons between groups
were analyzed using Student’s t-test. Statistical signifi-
cance is expressed as *p < 0.05; **p < 0.01; ***p < 0.001.
Results
Soluble E-selectin enhances the shear-resistant adhesion,
migration, and anoikis-resistant survival of CD44+/high
breast cancer cells
To investigate the effect of sE-selectin on factors
pertinent to hematogenous metastasis, we evaluated
shear-resistant adhesion, migration, and anoikis-resistant
survival using two estrogen receptor (ER)-negative/
CD44+/high BCs (MDA-MB-231 and MDA-MB-468), two
ER-positive/CD44-/low BCs (T-47D and MCF-7), and a
line of Tet-on inducible, E-selectin expressing, human
microvessel endothelial cells (ES-HMVECs) [26]. A
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confluent monolayer of ES-HMVECs was grown on a
collagen/fibronectin-coated parallel flow chamber and
was incubated with or without doxycycline for 4 h to in-
duce the expression of E-selectin. A single cell suspen-
sion of BCs was infused into a chamber to recapitulate
the shear-resistant adhesion of disseminated/circulating
tumor cells to vascular endothelial cells. The adherent
BCs were counted. Incubation of MDA-MB-231 and
MDA-MB-468 BCs with sE-selectin increased the
shear-resistant adhesion to doxycycline-untreated ES-
HMVECs (i.e., absence of E-selectin expression on ES-
HMVECs) 1.9 fold (p < 0.05) and 2.0 fold (p < 0.001),
respectively, compared with adhesion of saline-treated
BCs (Fig. 1a). The adhesion of saline-treated MDA-MB-
231 and MDA-MB-468 BCs to doxycycline-untreated ES-
HMVECs was negligible, but increased significantly when
E-selectin expression was induced in ES-HMVECs by
doxycycline (1.8 fold and 2.0 fold, respectively, p < 0.001).
The extent of shear-resistant adhesion of sE-selectin-
treated MDA-MB-231 and MDA-MB-468 BCs to un-
treated ES-HMVECs was similar to that of saline-treated
BCs to activated ES-HMVECs. In contrast, neither
sE-selectin nor endothelial E-selectin enhanced the
shear-resistant adhesion of ER+/CD44-/low MCF-7 and
T47D BCs. These results suggest the involvement of
CD44 in sE-selectin-mediated adhesion. Previously, we
demonstrated a physical interaction between E-selectin
and CD44 isolated from MDA-MB-231 BCs [13]; we then
examined the effect of sE-selectin in shRNA-mediated
CD44-knockdown MDA-MB-231 BCs. Soluble E-selectin-
induced shear-resistant adhesion was significantly reduced
in two CD44 knockdown clones of MDA-MB-231 BCs
(clone 28, 0.29 fold, and clone 36, 0.30 fold, p < 0.001) as
compared with saline controls (Fig. 1b).
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Fig. 1 Soluble E-selectin induces adhesion and migration of CD44+/high BCs: a Effect of sE-selectin on shear resistant adhesion of BCs to endothelial
cells. A monolayer of ES-HMVECs was grown on the flow chamber. For endothelial E-selectin expression, ES-HMVECs were incubated with or without
doxycycline (1500 ng/ml) for 4 h. BCs suspensions were incubated with 100 nM sE-selectin for 10 min and then were infused into flow chambers. The
shear-resistant adhesion of BC cell lines (105 cells/ml) was tested at 37 °C for 5 min at a rate of 1 dyn/cm2. BCs adhering to endothelial cells were
counted under a light microscope. Data were expressed as percentage of control (-Dox/-sEselectin as 100 %). b Effect of CD44 knockdown of MDA-
MB-231 cells on sE-selectin-induced shear-resistant adhesion. Suspensions of MDA-MB-231 cells with CD44 shRNA or control shRNA clone (105 cells/
ml) were treated with sE-selectin or saline and infused into flow chambers after a brief wash. The adhesion of the cells to non-activated ES-HMVECs
(-Dox) were counted under a light microscope. Data were expressed as percentage of control (saline treated as 100 %). c Effect of sE-selectin on the
migration of BCs. BCs were seeded into the upper chambers (12-μm pore), soluble E-selectin (100 nM) was added to the lower chambers, and plates
were incubated overnight at 37 °C. Migrated cells were stained using an HEMA3 staining kit and were counted under light microscopy. Data were
expressed as percentage of control (saline treated as 100 %). d Effect of CD44 knockdown of MDA-MB-231 cells on sE-selectin-induced migration.
CD44 knockdown clones of MDA-MB-231 cells or control shRNA were added to the upper chambers and migrated cells were counted after overnight
incubation at 37 °C. The data represent Mean ± S.D. *p < 0.05; **p < 0.01; ***p < 0.001 vs. saline, Student’s t-test. Data were summarized from an
experiment conducted in triplicate and repeated twice
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To further examine the role of sE-selectin on migra-
tion, we performed a Boyden chamber migration assay.
BCs were added to the upper chamber, while the lower
chamber contained culture media, with or without sE-
selectin. The presence of sE-selectin enhanced migration
of CD44+/high MDA-MB-231 BCs (1.8 fold, p = 0.006)
and MDA-MB-468 BCs (1.7 fold, p = 005) (Fig. 1c).
However, sE-selectin did not affect the migration of
CD44-/low MCF-7 BCs or T-47D BCs (Fig. 1c). Soluble E-
selectin-induced migration was also significantly reduced
in CD44 knockdown clones of MDA-MB-231 BCs
(Fig. 1d). Moreover, sE-selectin increased anoikis resist-
ance in MDA-MB-231 BCs (1.36 fold, p < 0.001) and
MDA-MB-468 BCs (1.16 fold, p = 0.02), but this effect
was not observed in MCF-7 and T-47D BCs (Additional
file 1: Figure S1). Therefore, these data suggest that sE-
selectin specifically enhances anoikis resistant survival,
shear resistant adhesion, and migration of CD44+/high BCs.
Soluble E-selectin enhances shear-resistant adhesion and
migration in leukocytes
To further assess the effect of sE-selectin on circulating
cells, leukocyte cell line HL-60 and human peripheral
blood mononuclear cells (PBMCs) were used in adhe-
sion and migration assays. Leukocytes (105 cells/ml)
were infused into a confluent monolayer of parental
HMVECs (p-HMVECs) grown on a collagen/fibronec-
tin-coated parallel flow chamber at 1 dyn/cm2 for 5 min
and the adherent cells were counted. Consistent with
the data from analysis of BCs, sE-selectin enhanced the
shear-resistant adhesion of HL-60 (1.6 fold, p < 0.001)
and PBMCs (2.1 fold, p < 0.001) to non-activated
pHMVEC (Fig. 2a). Additionally, sE-selectin enhanced
the migration of HL-60 (2.4 fold, p < 0.001), and PBMCs
(3.6 fold, p < 0.001) (Fig. 2b). Functional blockade of
CD44 in HL-60 using CD44 blocking antibody or a knock-
down resulted in reductions of sE-selectin-mediated adhe-
sion to non-activated p-HMVECs (p < 0.001). Taken
together, these results indicate that sE-selectin may have
biological function via CD44 in a broad range of circulat-
ing cells including leukocytes and cancer cells.
The shear-resistant adhesion of sE-selectin-treated
MDA-MB-231 BCs increases the permeability of
non-activated p-HMVECs
While leaky endothelium is a hallmark of tumor-
associated vasculatures, under physiologic conditions,
endothelial cells are connected through tight junctions.
Adhesion of cancer cells to the activated endothelium is re-
ported to induce endothelial permeability for subsequent
transendothelial migration [27, 28]. We next evaluated
whether the shear-resistant adhesion of sE-selectin-treated
MDA-MB-231 BCs enhanced the permeability of non-













Fig. 2 Soluble E-selectin enhances migration of human leukocytes
in vitro. a Effect of sE-selectin on the adhesion of leukocytes to
non-activated p-HMVECs. A monolayer of p-HMVECs was grown on
the parallel flow chamber. The cells (105 cells/ml) were incubated
with 100 nM sE-selectin for 30 min and then infused into the chamber
at 37 °C over a 5 min period at a shear stress rate of 1 dyn/cm2.
Adhesion was expressed as a percent relative to adhesion of saline-
treated control cells. b Migration assay was performed using Boyden
chamber. HL-60 cells (5 × 105 cells) were seeded in upper chambers
(5-μm pores) and 100 nM sE-selectin was supplemented to the lower
chambers. The number of migrated cells was counted after 16 h.
Migration is expressed as a percent relative to saline-treated control.
c Effect of CD44 knockdown of HL-60 on sE-selectin-induced adhesion.
The data represent Mean ± S.D. *p < 0.05; **p < 0.01; ***p < 0.001,
Student’s t test. Data were summarized as % of respective control
from an experiment conducted in triplicate and repeated twice
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MB-231 BCs was pre-incubated with sE-selectin or saline.
After a brief spin followed by washing with PBS, the cells
were layered onto a confluent monolayer of non-activated
p-HMVECs with 2000 kDa FITC-dextran as a fluorescent
tracer. Following the addition of sE-selectin-treated MDA-
MB-231 cells, a steep increase in fluorescent leakage
through the HMVEC monolayer was observed (Fig. 3a). In
contrast, the adhesion of saline-treated MDA-MB-231 BCs
to non-activated p-HMVECs did not have a significant
effect on endothelial permeabilization over the course of
the 60 min assay (Fig. 3a). Incubation of p-HMVECs with
sE-selectin alone had no effect on endothelial permeability
(data not shown). To confirm increased endothelial perme-
ability, the endothelial junction was immunostained after
the adhesion of BCs to non-activated p-HMVECs. A single
cell suspension of MDA-MB-231 BCs was treated with sE-
selectin and then washed with PBS to remove sE-selectin.
The cells were infused into a flow chamber at a rate of
1 dyn/cm2 for 5 min. After a brief wash, the cells were
fixed for immunostaining with VE-cadherin. The shear-
resistant adhesion of sE-selectin-treated MDA-MB-231
BCs to non-activated p-HMVECs resulted in the appear-
ance of a visible gap and disappearance of VE-cadherin
surface expression (Fig. 3b). These data suggest that the ad-
hesion of sE-selectin treated CD44+/high BCs permeabilizes
non-activated endothelium.
Soluble E-selectin activates focal adhesion kinase
To determine the underlying mechanism of sE-selectin-
mediated adhesion and migration, a single cell suspension
of MDA-MB-231 BCs was incubated with sE-selectin
for 5 to 60 min. Soluble E-selectin triggered the
phosphorylation of focal adhesion kinase (FAK) at
Tyr-397 after 5 min of incubation; whereas there were
no changes in total FAK expression (Fig. 4a). How-
ever, sE-selectin did not affect FAK phosphorylation
in the CD44sh 28 clone (Fig. 4a), suggesting the in-
volvement of CD44 in sE-selectin-mediated FAK
phosphorylation. To confirm the involvement of FAK
signaling in sE-selectin-mediated effects, adhesion as-
says were performed using pathway-specific inhibitors
at a concentration that did not affect cell viability
(Additional file 1: Figure S2). Suspensions of MDA-
MB-231 or HL-60 cells were co-incubated with sE-
selectin and FAK inhibitor (FAK inhibitor II, 5 μM)
for 30 min. After a brief spin followed by washing
with PBS, the cells were then infused into parallel
flow chambers. FAK inhibitor II abolished sE-selectin-
mediated shear-resistant adhesion to non-activated
HMVECs (Fig. 4b).
Pre-activation of 4 T1 BCs with sE-selectin results in
enhanced homing in vivo
To validate the effect of sE-selectin on hematogenous
metastasis, we used a mouse model of forced lung
metastasis. Murine 4 T1 BCs expressing luciferase (4T1-
Luc) were pre-incubated with mouse sE-selectin and
injected into wild-type Balb/C or E-selectin knockout
mice via tail vein. Seven days after the injection, the
mice were perfused with warm saline to remove residual
**
a b
Fig. 3 Incubation of breast cancer cells with sE-selectin increases permeability of p-HMVECs: a Effect of adhesion of sE-selectin-treated BC on endothelial
permeability. HMVECs were grown to confluence onto collagen-coated 0.4-μm-pore transwell chambers. MDA-MB-231 cells were pre-incubated with
sE-selectin or saline for 10 min and plated onto the upper chamber with 2000-kDa FITC-dextran. The same amounts of FITC dextran was added to the
control well without addition of MDA-MB-231 cells. The fluorescence in the lower chamber as a result of endothelial permeability was measured at
60 min after the addition of cells and dye. The data represent Mean ± SD. Statistical significance was determined by Student’s t-test (saline treated-MDA-
MB-231 vs. sE-selectin-treated MDA-MB-231). b Endothelial gap formation following adhesion of sE-selectin-treated MDA-MB-231 cells. MDA-MB-231 cells
treated with sE-selectin and infused into flow chambers over a 5 min period at a shear stress rate of 1 dyn/cm2. Cells were fixed for
10 min, immunostained with VE-cadherin (red), and counter-stained with DAPI (blue). The image was visualized by confocal microscope. Control
indicates addition of no cells
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cells in the circulation. Relative luciferase mRNA expres-
sion was measured in the lung. Pre-incubation of 4 T1
cells with sE-selectin increased homing to the lung
by 2.5 fold (p = 0.03) in wild-type mice and 1.7 fold
(p = 0.04) in E-selectin knockout mice compared with
saline-treated 4 T1-Luc (Fig. 5a). The increased extent
of lung homing in wild-type mice may be a conse-
quence of endogenous E-selectin expression on the
vessel or sE-selectin shed after activation in wild-type
mice. To identify cellular adhesion molecules (CAMs)
that support endothelial E-selectin-independent/sE-
selectin-mediated shear-resistant adhesion, functional
blocking antibodies against ICAM or VCAM were
used to pretreat non-activated p-HMVECs for 1 h
prior to the flow adhesion assay. The pre-incubation
of non-activated p-HMVECs with ICAM-1 blocking
antibody resulted in a significant reduction of sE-
selectin-mediated shear-resistant adhesion; whereas,
VCAM-1 blockade did not affect sE-selectin-mediated
shear-resistant adhesion (Fig. 5b).
Pre-activation of human PBMCs with sE-selectin stimulates
tumor growth
To confirm pleiotropic effects of sE-selectin, we next
explored the biological consequences of leukocyte activa-
tion by sE-selectin on tumor growth in vivo. Human
PBMCs were freshly isolated from healthy donors and la-
beled with Calcein AM, then pre-treated with sE-selectin
for 30 min at 37 °C. The PBMCs were infused via tail vein
into NSG mice bearing human breast tumors derived
from MDA-MB-231. Infiltration of Calcein positive
PBMCs was measured by fluorescence-activated cell sort-
ing (FACS) and visualized by fluorescent microscopy. Fol-
lowing a single intravenous infusion of sE-selectin-treated
PBMCs, 1.45 ± 0.08 % of tumor cells were Calcein-
positive, whereas, only 0.14 ± 0.1 % of tumor cells were
Calcein-positive in mice receiving saline-treated PBMCs.
This amounts to a ten-fold increase in PBMC infiltration
when PBMCs are exposed to sE-selectin prior to infusion
(p < 0.001) (Fig. 6a). Fluorescence microscopic analysis
further confirmed that pre-incubation of PBMCs with sE-
selectin resulted in an increased infiltration of Calcein-
positive PBMCs into tumors, compared with tumor from
mice infused with saline-treated PBMCs (Fig. 6a). Next,
we evaluated whether the infiltration of sE-selectin-
treated PBMCs into the tumor affected tumor growth.
PBMCs treated with or without sE-selectin were infused
at day 18 and 25 into NSG mice bearing MDA-MB-231
breast tumors carrying the luciferase gene (n = 5). Tumor
growth was measured weekly at day 10, 16, 22 and 29 by
bioluminescence. PBMCs were infused, and on day 22
(4 days post- PBMC infusion), we found that infusion of
sE-selectin-treated PBMCs had increased tumor growth
by 3.6 fold when compared to day 16 (prior to infusion).
In contrast, in the mice receiving saline-treated PBMCs,
only 1.4 fold tumor growth was noted. The differences in
tumor growth rates between these groups were significant
at four days after infusion (2.6 fold, p < 0.05). This trend
remained the same at 29 days (Fig. 6b). FACS analysis of
tumors further confirmed the presence of human CD45+
cells after two consecutive infusions of human PBMCs
(Fig. 6c). Infusion of sE-selectin treated of PBMCs in-
creased intratumoral infiltration by human CD4+ T-
lymphocytes (20.2 %) significantly more than infusion of
saline treated control PBMCs (11.5 %), but did not affect
infiltration of CD8+ T-lymphocytes or CD68+ cells. Of
note, the CD4/CD8 ratios of PBMCs used in this study
were almost the same (CD4: 39.1, CD8: 37.2; Additional
file 1: Figure S3). These data suggest that sE-selectin is a
biologically functional signaling molecule in circulation
after shedding and enhances the shear-resistant adhesion
and migration of a broad range of CD44+ circulating cells
(metastatic cancer cells or leukocytes), which additively
promote disease progression via stromal development and
homing of metastatic BCs to the lung.










sES - + - + - + - +
FAK - - + + - - + +
HL60 MB-231
Fig. 4 Soluble E-selectin triggers FAK activation: a Activation of FAK
by sE-selectin in MDA-MB-231. An MDA-MB-231 suspension was
incubated with sE-selectin (100 nM) for the indicated period of time
(0-60 min). CD44 shRNA knockdown clones or control shRNA of
MDA-MB-231 cells (clone 28) were incubated with sE-selectin for the
indicated time. Cell lysate (30 μg) was separated by SDS-PAGE and
probed with pFAK (Y397) and total FAK, followed by HRP-conjugated
secondary antibody. GAPDH was used as a loading control. The blot
was visualized by ECL. b FAK inhibitor blocks sE-selectin-mediated
adhesion. MDA-MB-231 or HL-60 cells were co-incubated with vehicle
alone, sE-selectin, FAK inhibitor II (5 μM), or sE-selectin + FAK inhibitor II
for 30 min in a rotation wheel. After a brief wash with PBS, the cells
were infused into parallel flow chambers over a 5 min period at a shear
stress rate of 1 dyn/cm2. The adherent cells were counted under a
microscope. The data were summarized as fold increase of adhesion of
MDA-MB-231 and HL60 cells. The data represent Mean ± SD. Statistical
significance was determined by Student’s t-test
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Fig. 5 Soluble E-selectin enhances homing of 4T1 cells to the lung in mice: a Effect of sE-selectin on infiltration of 4 T1 cells into the lung. Luciferase-
expressing 4 T1 murine breast cancer cells were pre-incubated with sE-selectin (100 nM) and, following washing with PBS to eliminate sE-selectin
carryover, were intravenously injected into female Balb/C or E-selectin knockout mice. Seven days later, lungs were harvested and luciferase mRNA
was analyzed by qRT-PCR and normalized by GAPDH. The data represent Mean ± SD. Statistical significance was determined by Student’s t-test.
b sE-selectin-mediates adhesion is ICAM-1 dependent. Parental-HMVECs were pre-incubated with monoclonal antibody (1 μg in 100 μl) against
ICAM-1 or VCAM-1 or the same amount of normal IgG for 1 h at 37 °C prior to the adhesion assay. After a brief wash, MDA-MB-231 BCs that were
treated with sE-selectin for 30 min were infused into parallel flow chambers. The data represent Mean ± S.D. **p < 0.01; ***p < 0.001 vs. -/-, Student’s






















Fig. 6 Soluble E-selectin enhances infiltration of PBMCs into tumor and tumor growth in NSG mice: a Human PBMC infiltration into breast tumor.
Freshly isolated PBMCs were labeled with Calcein AM, followed by incubation with 100 nM sE-selectin for 15 min. After a brief washing to eliminate
sE-selectin carryover, PBMCs (2 × 107 cells) were infused into NSG mice bearing orthotopic breast tumors derived from MDA-MB-231 breast cancer cells
(n = 4). Tumors were isolated 4 days after PBMC infusion and the numbers of Calcein-positive cells were counted by FACS. The histogram represents
Mean ± SE (n = 4 mice). Frozen sections (5 μm) were stained with Hoechst 33342 (blue) to label nuclei. b Tumor growth following PBMC infusion.
MDA-MB-231-luc cells was injected into mammary fat pad of NSG mice at day 0 and tumor growth was measured at day 10 and 16 to confirm similar
growth rate between two groups. On day 18 and 25, human PBMCs (107 cells) were infused via tail vein (red arrow) and tumor growth after the
infusion was measured on day 22 and 29. Tumor growth was measured using bioluminescent imaging. The graph indicates photon flux from mice
infused with PBMCs pre-incubated with saline (dashed line) or 100 nM sE-selectin (solid line). The data represent Mean ± SE (n = 5). c FACS analysis of
human CD45+ leukocyte populations in the tumor. Tumors were harvested and single cell suspensions were labeled with human CD45, CD4, CD8,
and CD68, and were analyzed by flow cytometry
Kang et al. BMC Cancer  (2016) 16:331 Page 8 of 13
Discussion
Circulating E-selectin, sE-selectin, is a byproduct of
endothelial E-selectin that originates from the external
domain of E-selectin expressed on activated endothelium
as a result of enzymatic cleavage or shedding from
damaged or activated endothelial cells [29]. Several
studies have reported chemotactic effects of sE-selectin
in different cell types, including endothelial cells and
leukocytes [30–32]. However, the effects of sE-selectin in
tumor progression and metastasis is largely unknown.
We and others have previously reported that the en-
gagement of CD44 with endothelial E-selectin medi-
ates shear-resistant adhesion of BCs and leukocytes to
endothelial cells [13, 14, 33]. In addition to describing
the roles of endothelial E-selectin, we found that sE-
selectin functions as a circulating signaling molecule
that potentiates shear-resistant adhesion and migra-
tion of CD44+/high BCs and leukocytes in an endothe-
lial E-selectin independent fashion and facilitates
tumor progression and metastasis.
The adhesion cascade is governed by cell-cell interac-
tions between circulating cells and endothelial cells via a
sequential affinity interaction between adhesion mole-
cules and the counter-receptor ligand. Thus, the ablation
of adhesion molecules, such as selectins, ICAM-1, or
VCAM-1, significantly impairs leukocyte infiltration.
Given the E-selectin’s integral role in tissue infiltration
as the first step mediator of adhesion, endothelial E-
selectin-independent homing and shear-resistant adhe-
sion of BCs and leukocytes were unexpected. Our data
demonstrate that sE-selectin-mediated activation of the
CD44/FAK axis of BCs enables ICAM-1-dependent
adhesion at low shear stress, bypassing the requirement
for engagement with endothelial E-selectin. A bypass of
initial adhesion via endothelial E-selectin may occur
when abundant CD44+ cells and circulating sE-selectin
encountered endothelium expressing ICAM-1 at low
shear stress. Similar bypass mechanism was reported by
Thankamony and Sackstein as a novel paradigm of cell
migration termed the “step 2-bypass pathway’”. The step
2-bypass pathway permits transendothelial migration of
mesenchymal stem cells through interaction of endothe-
lial VCAM-1 with activated VLA-4 without engagement
of the chemokine receptors (CXCR4 and SDF-1) [34].
These data suggest the presence of alternative adhesion
mechanisms that are supported by CAMs. In fact, the
expression of CAMs is primarily induced by inflamma-
tory cytokines; however, low levels of constitutive ex-
pression occurs in some organs and endothelial cell lines
[35–37]. Additionally, double knockout of ICAM/
VCAM is lethal [38, 39], while triple knockout of selec-
tins (E-, P-, and L-selectin) does not completely ablate
tissue infiltration of leukocytes to wounded areas [40].
These collectively indicate the presence of a selectin-
independent alternative adhesion, which may be compen-
sated by constitutive CAMs expression. This poses the
question of whether individuals with breast cancer and
synchronous chronic inflammation who have elevated sE-
selectin and CD44+ circulating tumor cells (CTCs) are pre-
disposed to increased risk of organ metastasis. Our data
suggested that serum sE-selectin levels were associated
with tumor size (Additional file 1: Figure S4). Additionally,
several studies demonstrated positive correlations between
high sE-selectin levels and worse clinical outcome [25, 41–
43]. Sheen-Chen et al., reported that an elevated level of
sE-selectin is significantly associated with advanced tumor
size, lymph node involvement, metastasis, high histology
grade, and reduced overall survival in breast cancer. The
study further indicated that women with ER-negative
breast tumors had a significantly higher level of sE-selectin
than those with ER-positive breast tumors [41]. Similarly
to cancer, elevated sE-selectin was also noted in individ-
uals with chronic inflammation disorders including
arthritis [44], diabetes [45], atherosclerosis [46], and
alcoholism [47]. Our data demonstrated cellular re-
sponses to sE-selectin were concentration dependent
and reached a plateau at 100 nM (Additional file 1:
Figure S5); therefore, we used 100 nM sE-selectin in
this study (equal to approx. 5.8 μg/ml when calcu-
lated as MW: 60 kDa). While the association of tissue
inflammation and cancer progression has been re-
ported [48, 49], future study should address a possible
link regarding how chronic inflammation affects can-
cer cell behavior in vascular space.
The effect of sE-selectin was highly specific to CD44+/high
BCs; its effect was minor or undetectable in CD44-/low BCs
and CD44 K/D MDA-MB-231 BCs. CD44 (HCELL) [34],
belongs to a family of cell-surface glycoproteins, and differ-
ential forms of CD44 (e.g., CD44s and CD44v) are
expressed in a variety of human leukocytes and solid tu-
mors. Despite its lack of intrinsic catalytic activity, CD44
plays a role in the activation of signaling pathways through
association with intracellular and extracellular proteins.
CD44 interacts with various soluble extracellular compo-
nents or ECM. Ligand binding to CD44 has been associ-
ated with numerous cellular processes such as migration,
adhesion, signaling, and proliferation [50]. For example,
the interaction of CD44 and its ligand, hyaluronic acid
(HA), results in proliferation of eosinophils [51], B-cells
[52], T-cells [53], keratinocytes [54], and human melanoma
cells [55]. In addition to HA, L-selectin and E-selectin are
reported to be ligands for distinct glycoforms of CD44 or
CD44v, respectively [56]. The interaction of CD44 with Src
family protein kinase, Rho-kinase, Tiam 1, and Vav2 trig-
gers intracellular activation of PI3K, Ras, and Rac1, which
promote cell migration, proliferation, and survival [57–61].
Although mounting evidence suggests the involvement
CD44 in tumor progression, the roles of CD44 as well as
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its utility as a biomarker for primary tumors remains con-
troversial due to its dual functions as a tumor promoter or
suppressor and altered expression in CD44v [37, 38]. How-
ever, recent studies highlighted the positive association of
CD44+ CTCs with hematogenous metastasis. The presence
of CD44+ CTCs is linked to bone metastasis [62] and cor-
relates with poor prognosis in breast cancer [63, 64]. While
the CD44 has been used as a stem cell marker, our data
suggest that CD44 may have functional role in
hematogenous metastasis in the circulation 1) as a ligand
for endothelial E-selectin at the pre-metastatic niche [13]
and 2) as a signaling molecule that mediates sE-selectin-
induced extrinsic stimuli in circulating cells.
Abundant leukocyte infiltration into the tumor is
associated with poor prognosis in many types of
cancer including breast, prostate, lung cancer, and
melanoma [48, 65, 66]. Our results demonstrate that
sE-selectin enhancement of leukocyte migration is
partially mediated by CD44. We used humanized
NOD SCID IL2R-γ chain knockout mice, which are
deficient in T-lymphocytes, B-lymphocytes, and NK
cells, to recapitulate the effect of crosstalk between
the human immune system and human cancer cells.
Mice receiving human PBMCs treated with human sE-
selectin showed rapid tumor growth, which coincided
with increased intratumoral infiltration of PBMCs, in
particular, CD4+ T-lymphocytes (Fig. 6c). Although we
expected the CD4+/CD8+ balance shift to trigger pro-
inflammatory signaling that would lead to an increase in
the human CD68+ macrophage population, no change
was noted in CD68+ cells or CD8+ T-lymphocytes. A
separate study showed that sE-selectin-mediated tumor
growth was not as significant when mouse splenocytes
were infused into athymic nu/nu mice bearing xenograft
tumors derived from MDA-MB-231 cells (data not
shown), although infiltration of mouse PBMCs into the
tumor was more extensive than that of human PBMCs
(Additional file 1: Figure S6). Possibly, there is a slight
discordance between adaptive immune cells from human
and innate immune cells and vessels of mice.
In conclusion, we proposed possible simultaneous and
multifaceted effects of E-selectin in tumor growth and
metastasis in Fig. 7: endothelial E-selectin mediates the
shear-resistant adhesion of circulating tumor cells and
immune cells to inflamed vessels (a), but not to non-
inflamed vessels (b); sE-selectin shed into circulation
accelerates homing of CD44+ BCs into tissue via non-
inflamed vessels, endothelial E-selectin independent/
ICAM dependent manner (c); sE-selectin accelerates the
infiltration of CD4+ lymphocytes into the tumor to con-
tribute to the development of inflammatory stromal (d).
Conclusion
Soluble E-selectin (sE-selectin) is shed into the circulation
from the activated endothelium. We investigated the effect
of sE-selectin on shear-resistant adhesion and migration
of metastatic breast cancer cells and leukocytes. Our data
suggest that sE-selectin promotes migration and shear-
Fig. 7 Scheme of sE-selectin-mediated shear-resistant adhesion and migration: a The expression of adhesion molecules such as E-selectin, ICAM, and
VCAM is induced in the luminal surface of inflamed vessel. Margination of leukocytes and CD44+/high BCs toward the vessel surface is followed by
tethering, rolling, and adherence to inflamed vessels. The adhesion of the cells increases the permeability of endothelial junctions facilitating tissue
migration of circulating cells. b By contrast, in a non-inflamed vessel, circulating cells remain in circulation and no random adhesion occurs. c Soluble
E-selectin is shed from activated endothelium of inflamed tissues and activates both leukocytes and CD44+/high BCs, which enhances their shear resistant
adhesion to non-inflamed vessels and migration in the absence of E-selectin but via interaction with ICAM at low shear stress. Excessive infiltration of CD4+
T-lymphocytes into the tumor leads to development of pro-tumorigenic stroma. Infiltration of CD44+/high BCs into distant organ increases the risk of
colonization by metastatic cells
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resistant adhesion of circulating cells to non-activated
HMVECs via CD44/FAK. This sE-selectin-mediated
pleiotropic effects result in enhancement of homing
of CD44+/high BCs and immune cells to the lung and
tumor, respectively. These findings identify a possible
extrinsic mechanism by which serum factor stimulates
circulating tumor cells toward tumor progression and
metastasis.
Additional files
Additional file 1: Supplementary Figure 1. Soluble E-selectin
enhances the anoikis resistance of ER-negative BCs: BCs were suspended
(104 cells) in 1% FBS media with or without sE-selectin, and seeded in
ultra-low attachment plates. The data represent the increased percentage
of surviving cells with sE-selectin. The data shown are Mean ± SD.
Supplementary Figure 2. The effect of FAK kinase inhibitors on cell
viability: (a) HL-60 cells were incubated with the indicated concentrations
of FAK inhibitor for 30 min. The viable cells were counted using a
Neubauer hemocytometer 24 hours later. (b) MDA-MB-231 cells were
incubated with the indicated concentrations of FAK inhibitor for 30 min.
The cell viability was measured by MTT assay. Supplementary Figure 3.
Profile of human PBMCs: PBMCs were isolated from freshly isolated
human buffy coat of healthy donors. PBMCs were analyzed by flow
cytometry using a FACS Calibur. Supplementary Figure 4. Detection of
sE-selectin in the serum from mice bearing tumor: MDA-MB-231 cells
(3x104 or 3x105 cells) were injected into mice (n=4). Two weeks later,
whole blood was collected and serum was collected. Soluble E-selectin
level was measured by ELISA. The data shown are Mean ± SD.
Supplementary Figure 5. Soluble E-selectin enhances migration of
MDA-MB-231 in sE-selectin dose dependent manner: Boyden chamber
assay was performed. The migrated cells were stained using an HEMA3
staining kit and were counted under light microscopy. Data were
expressed as percentage of control (saline treated as 100%). The data
represent Mean ± S.D. Supplementary Figure 6. Mouse splenocyte
infiltration into human tumor: Mouse splenocytes were isolated from
Athymic nu/nu mice and labeled with Calcein AM (green). The labeled
splenocytes (107 cells) were infused intravenously into mice bearing
tumors derived from MDA-MB-231 BCs. Tumors were harvested and
frozen sections were counterstained with Hoechst 33342 (blue) and
visualized using a fluorescent microscope at ×200. (PPTX 4183 kb)
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